China, Sept. 30 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Multimodal Artificial Intelligence Framework for the Diagnosis and Prognostic Evaluation of TFE3-Rearranged Renal Cell Carcinoma'. The following are the other relevant details related to the trial:
Registration Number: ChiCTR2600133567
Registration Time: 2026/09/29
Type: Observational study
Primary Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337143
Published by HT Digital Content Services with permission from Health Daily Digest....